Chondrosarcoma
MONDO:0008977A malignant cartilaginous matrix-producing mesenchymal neoplasm arising from the bone and soft tissue. It usually affects middle-aged to elderly adults. The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.
Also known as: chondrosarcoma, chondrosarcoma (disease), chondrosarcoma, malignant, chondrosarcoma, somatic mutation, chondrosarcoma of bone, primary chondrosarcoma of the bone
2805 clinical trials for this condition and its sub-types, 39 tagged with Chondrosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Chondrosarcoma
-
Bone chondrosarcoma 1 trial · 10 incl. sub-types
3 sub-types
- Dedifferentiated chondrosarcoma 9 trials
- Clear cell chondrosarcoma 3 trials
- Periosteal chondrosarcoma 0 trials
-
Mesenchymal chondrosarcoma 4 trials
2 sub-types
- Adult mesenchymal chondrosarcoma 0 trials
- Pediatric mesenchymal chondrosarcoma 0 trials
-
Myxoid chondrosarcoma 2 trials
2 sub-types
- Adult myxoid chondrosarcoma 0 trials
- Pediatric myxoid chondrosarcoma 0 trials
-
Localized chondrosarcoma 0 trials
-
Cancer drug regorafenib tested to halt bone sarcoma spread
Disease control CompletedThis phase 2 trial tests whether the drug regorafenib can stop or slow the growth of metastatic bone sarcomas (cancers that started in bone and spread). 163 patients with osteosarcoma, Ewing sarcoma, chondrosarcoma, or chordoma are randomly assigned to receive regorafenib or a pl…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New pill targets genetic flaw in tough cancers
Disease control CompletedThis early-phase trial tested an oral drug called AG-120 in 174 people with advanced solid tumors (including bile duct cancer, cartilage cancer, and brain tumors) that have a specific IDH1 mutation. The study first found a safe dose, then expanded to see how well the drug works. …
Phase 1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Proton beam therapy tested for rare spine and skull base tumors
Disease control CompletedThis study tested proton beam therapy in 54 adults with chordomas or chondrosarcomas, rare tumors of the skull base and spine. The goal was to see if this precise radiation approach is feasible and safe, and to track both short- and long-term side effects. Researchers monitored h…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Real-World data reveals gaps in bone cancer care
Knowledge-focused CompletedThis study looked back at the medical records of 545 patients with bone tumors that had spread (metastatic). The goal was to see how these patients were treated in real life and what their outcomes were. The study focused on three types of bone tumors: osteosarcoma, Ewing sarcoma…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC